Medicated drinking water systems for poultry and swine require flumequine veterinary-grade API to be converted into water-soluble powders or granules that dissolve rapidly in cool water and remain in solution for a defined farm use period. Flumequine is weakly acidic and exhibits pH-dependent aqueous solubility; dissolution in neutral or hard water is slow. Formulators therefore incorporate alkalizing agents such as anhydrous sodium carbonate or trisodium citrate at 1.5–3.5 molar equivalents relative to the API. A representative drinking-water powder contains flumequine at 5–20% w/w, lactose monohydrate or dextrose as diluent, povidone K30 at 2–5% w/w as granulation binder, and crospovidone or sodium starch glycolate at 2–4% w/w as disintegrant. Citric acid or disodium EDTA at 1–3% w/w is added when farm water contains calcium, magnesium, or iron above 200 mg/L as CaCO3; these polyvalent cations chelate fluoroquinolones and reduce dissolved active concentration. The API is pre-blended with half the diluent in a high-shear granulator, then granulated with purified water or an aqueous povidone solution. Wet mass is passed through a 1.5–2.0 mm screen and dried in a fluid-bed dryer with inlet air temperature 55–70 °C until loss on drying is ≤2.0%. Dried granules are screened through 0.8 mm, blended with extragranular disintegrant and colloidal silicon dioxide at 0.5–1.0% w/w, and filled into sachets or drums. Each batch is tested by high-performance liquid chromatography per Ph. Eur. 2.2.29 for assay and related substances. The terminal drinking-water solution is prepared at the farm by adding the powder to water at 20–25 °C with slow agitation; concentrated stock solutions should not be prepared with hard water unless a chelating agent is present. Published flumequine-specific solubility data in hard water matrices are limited, so farm dilution protocols are generated from site-specific water quality records rather than extrapolated from laboratory tests.

Why Terminal pH Conditions Dictate Injectable Solution Stability in Cattle and Swine Formulations

Injectable formulations of flumequine present a pH-solubility conflict. The API is practically insoluble in neutral aqueous vehicles, but excessive alkalinity causes injection-site irritation and may compromise tissue tolerance in cattle and swine. A typical injectable solution is prepared at 50–100 mg/mL by dispersing flumequine in water for injection, then adding 1 M sodium hydroxide or meglumine under constant stirring until the pH reaches 9.0–10.0. Once dissolved, the solution is cooled to 20–25 °C and the pH is checked again because temperature drift shifts dissociation equilibrium. Sodium metabisulphite at 0.1% w/v may be added as antioxidant, and benzyl alcohol at 1.5–2.0% v/v is used as preservative in multidose vials. The finished solution is filtered through a 0.22 μm PVDF or polyethersulfone membrane. If terminal moist-heat sterilisation at 121 °C for 15 min is applied, the formulation must demonstrate degradation products below the reporting threshold in accelerated and long-term stability studies according to VICH GL3. When heat-labile or pH-sensitive, sterile filtration into sterile type I glass vials is used. Headspace nitrogen purging reduces oxygen ingress in alkaline solutions. Compatibility with closure elastomers must be verified because some rubber stoppers release leachables or adsorb the API under alkaline conditions. Polypropylene or type I glass containers are preferred. The solution must not be diluted with lactated Ringer’s injection, Hartmann’s solution, or any diluent containing calcium or magnesium ions; polyvalent cations form poorly soluble complexes with fluoroquinolones and may precipitate immediately. Dosing in cattle and swine is based on body weight and veterinary prescription, and the final injection volume is adjusted accordingly. Injection site reaction studies and local tolerance data are required for regulatory dossiers because the alkaline pH and preservative system can influence pain scores on repeated administration.

Production-scale mixing of injectable solutions uses jacketed stainless-steel vessels with bottom-entry high-shear agitators and nitrogen overlay. Mixing speed is maintained below 300 rpm after the API has dissolved to minimise oxygen entrainment. The solution is recirculated through a 0.45 μm prefilter and a 0.22 μm final sterilising-grade membrane. Vessel and filter hold-up volumes are minimised because the active concentration changes if line flushing is incomplete. In-process tests include pH, clarity, density, and filter integrity using bubble-point or diffusive-flow methods. Published flumequine-specific pH-solubility curve data remain limited; formulation development must characterize solubility at 20 °C and 40 °C before scaling to commercial batch sizes.

During the compression of flumequine tablets and the filling of capsules for oral administration in calves and companion animals, particle-size distribution of the API controls blend uniformity and dissolution. Flumequine API is often produced as a fine crystalline powder; if d50 is below 40 μm, direct compression can create segregation during hopper discharge and sticking on punch faces. Wet granulation is therefore used to densify the API and reduce batch-to-batch variation. A representative tablet granulation contains flumequine at 20–50% w/w, microcrystalline cellulose at 20–40% w/w, lactose monohydrate or dibasic calcium phosphate dihydrate as filler, povidone K30 at 3–5% w/w as binder, croscarmellose sodium at 2–4% w/w as disintegrant, and magnesium stearate at 0.5–1.0% w/w as lubricant. The granulation is dried to moisture ≤2.0% in a fluid-bed dryer at product temperature 40–45 °C. Tablets are compressed on a rotary press at 40–80 rpm with compaction force adjusted to produce hardness 6–10 kp measured on a Schleuniger hardness tester. Friability is controlled at ≤1.0% per Ph. Eur. 2.9.7, disintegration time is ≤15 min per Ph. Eur. 2.9.1, and dissolution is evaluated per Ph. Eur. 2.9.3. Because flumequine has limited solubility in acidic media, dissolution testing may require a surfactant-containing medium such as 0.5% sodium dodecyl sulfate in phosphate buffer pH 6.8 to achieve sink conditions. Capsule formulations replace the tableting filler with finer lactose or pregelatinised starch and are filled on automatic dosator or tamping-pin machines. Powder flow for capsule filling is improved with 0.5–1.0% w/w colloidal silicon dioxide. The terminal products are aluminium-PVC or Aclar blisters for tablets and PVC/PVDC blisters for capsules; desiccant is added when moisture uptake exceeds 0.5% in accelerated stability. The following compendial test matrix is applied to each release batch:

When Feed-Mill Premix Carriers Exceed Critical Moisture Thresholds

Feed-mill premix production introduces flumequine into integrated poultry and swine feed at inclusion rates defined by veterinary prescription. Carrier selection determines segregation potential, dust formation, and chemical stability. Ground corn cob, wheat middlings, or lactose-based carriers are used at 80–90% w/w, with flumequine active content typically 5–10% w/w. Calcium carbonate as sole carrier is avoided because calcium ions can chelate the fluoroquinolone carboxylate and reduce systemic availability after feed ingestion. Carrier moisture is controlled at ≤10.0%; above 12.0% hydrolysis of the API accelerates and recovered assay after 6 months can fall below the shelf-life specification. Mixing is performed in a horizontal double-ribbon mixer or paddle mixer at 50–80% nominal fill for 15–20 min, with coefficient of variation of assayed samples ≤5.0%. A two-step dilution is used: first a 1:10 intermediate blend is prepared, then this intermediate is incorporated into the final premix. Flush cycles with ground maize between batches reduce carryover below 0.1% and prevent cross-contamination with ionophore coccidiostats or other medicated premixes. During feed pelleting, conditioned meal temperature is kept between 70–85 °C for 20–40 s; if the line exceeds 85 °C, post-pelleting assay recovery should be verified because degradation kinetics are formulation-specific. The terminal product is a granular premix filled into multiwall paper bags with inner polyethylene liner or bulk discharge into dedicated bins.

Horizontal mixer shafts with worn ribbon clearances above 3 mm produce dead zones and assay variability; regular clearance verification is required. Premix plants operate under FAMI-QS certification or equivalent GMP+ feed safety assurance. Batch-level records include carrier moisture, mixer load, mixing time, and assay of 10 sampling points. Published data for flumequine stability under commercial pelleting conditions in all carrier types is limited; each manufacturing site therefore validates the premix under worst-case steam conditioning and post-pelleting retention time.

When flumequine is added to recirculating aquaculture systems, raceways, or hatchery tanks, dissolution is governed by water temperature, carbonate hardness, and pH. Direct addition of powder to tank water causes localised alkaline spikes and precipitation that reduces the dissolved dose available to fish. A concentrated stock solution is therefore prepared separately in 0.1 M sodium hydroxide at 10–20 mg/mL, with slow stirring until clear. This stock is metered into the inflow water over 15–30 min using a peristaltic pump; exposure duration in the tank is typically 2–6 h according to prescription and species-specific withdrawal requirements. Water hardness above 200 mg/L as CaCO3 reduces dissolved flumequine because calcium and magnesium form complexes with the fluoroquinolone carboxylate; if source water exceeds this value, a chelating agent such as disodium EDTA at 1–5% w/v of stock solution is added or the stock is diluted with softened water. Temperature is maintained at 20–28 °C during treatment; lower temperatures slow dissolution and fish uptake. UV disinfection units operating at 254 nm are switched off during treatment unless photostability data confirm acceptable loss below 5% over the exposure period. Ozone or activated carbon is used to deactivate residual flumequine in discharge water before release, because fluoroquinolones can persist in aquatic sediments and select for resistant bacteria. The terminal product is a medicated water volume that must be recorded in the aquaculture health log with batch number, measured water hardness, pH, temperature, and flow rate.

Flow-through tanks with counterflow injection produce different dissolved concentration gradients than static immersion. Peristaltic pumps with silicone tubing should be calibrated against backpressure from tank height. Aeration is maintained above 5 mg/L dissolved oxygen to avoid stress during treatment. Published flumequine-specific photostability data in aquaculture matrices is limited; site-specific validation is required before UV or ozone-assisted discharge treatment is scaled up.

Stabilised Oral Granule Suspensions for Neonatal Ruminants

In neonatal ruminant dosing, flumequine oral granules are dispersed rather than fully dissolved, because the API remains poorly water-soluble at neutral pH. The reconstituted suspension is used for oral drench or nipple feeding in calves and lambs. A typical granule formulation contains flumequine at 10–30% w/w, sucrose or lactose as diluent, xanthan gum at 0.2–0.5% w/v after reconstitution or carboxymethylcellulose sodium at 0.5–1.0% w/v as suspending agent, and potassium sorbate at 0.1% w/v as preservative. The granules are prepared by wet granulation in a high-shear granulator, dried at 45–50 °C product temperature, and filled into single-dose sachets. Reconstitution is performed with water at 20–30 °C; the mixture is shaken gently for 30–60 s and used within 24 h. Once reconstituted, the suspension should not be mixed with milk replacer containing high calcium unless compatibility is confirmed, because calcium ions may reduce flumequine absorption by forming poorly absorbed complexes in the gastrointestinal tract. The pH after reconstitution is controlled at 6.5–7.5 to reduce oral irritation in neonatal animals. Settling volume after 6 h is measured and should be ≥0.9 when redispersed by shaking. Assay and related substances are determined by HPLC per Ph. Eur. 2.2.29. The terminal product is a white to pale yellow granule in a sachet, labelled with reconstitution volume, species, and withdrawal period. Production-scale filling lines require humidity control below 40% RH to prevent granule sticking in dosing chamber. Batch-to-batch variance in granule density is controlled by sieve fraction analysis; granules passing through 0.5–1.0 mm sieve are preferred for consistent reconstitution behaviour.